Sisram Medical has restructured its DAXXIFY (prabotulinumtoxinA) distribution agreement in China, now involving a connected Fosun unit. DAXXIFY, a long-acting botulinum toxin approved in the U.S. and EU, represents a competitive challenge to Botox and Dysport in markets where practitioners seek extended duration and reduced re-treatment frequency.